{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:52:19Z","timestamp":1791420739496,"version":"4.3.3"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["fertstertreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["F&S Reports"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.xfre.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T05:33:30Z","timestamp":1676957610000},"page":"206-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome"],"prefix":"10.1016","volume":"4","author":[{"given":"Michael C.","family":"Snabes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juki","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izna","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Shebley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Schlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xfre.2023.02.007_bib1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2023.02.007_bib2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/humrep\/det469","article-title":"The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone","volume":"29","author":"Lauritsen","year":"2014","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.007_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.xfre.2023.02.007_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/biomedicines7010005","article-title":"Hypothalamic-pituitary-ovarian axis disorders impacting female fertility","volume":"7","author":"Mikhael","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.xfre.2023.02.007_bib5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr Rev"},{"key":"10.1016\/j.xfre.2023.02.007_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.tem.2018.08.005","article-title":"New perspectives on the pathogenesis of PCOS: neuroendocrine origins","volume":"29","author":"Walters","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.xfre.2023.02.007_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ng.306","article-title":"TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction","volume":"41","author":"Topaloglu","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.xfre.2023.02.007_bib8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1073\/pnas.1415038112","article-title":"Enhancement of a robust arcuate GABAergic input to gonadotropin-releasing hormone neurons in a model of polycystic ovarian syndrome","volume":"112","author":"Moore","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xfre.2023.02.007_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1210\/jcem-73-4-811","article-title":"Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease","volume":"73","author":"Fauser","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2023.02.007_bib10","first-page":"2248","article-title":"Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome","volume":"82","author":"Taylor","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2023.02.007_bib11","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/humrep\/12.6.1156","article-title":"Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment","volume":"12","author":"Cheung","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.007_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1210\/endo-109-2-376","article-title":"Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey","volume":"109","author":"Wildt","year":"1981","journal-title":"Endocrinology"},{"key":"10.1016\/j.xfre.2023.02.007_bib14","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/jm8006454","volume":"51","author":"Chen","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.xfre.2023.02.007_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1210\/jc.2008-1695","article-title":"Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix","volume":"94","author":"Struthers","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2023.02.007_bib16","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1210\/jc.2016-3845","article-title":"Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women","volume":"102","author":"Ng","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xfre.2023.02.007_bib17","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/humrep\/13.9.2392","article-title":"Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers","volume":"13","author":"Duijkers","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.xfre.2023.02.007_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfre.2023.02.007_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000002675","article-title":"Long-term outcomes of elagolix in women with endometriosis: results from 2 extension studies","volume":"132","author":"Surrey","year":"2018","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.xfre.2023.02.007_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xfre.2023.02.007_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1530\/eje.0.1310280","article-title":"Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women","volume":"131","author":"Sommer","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.xfre.2023.02.007_bib22","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1530\/eje.0.1310286","article-title":"Inhibition of luteinizing hormone, follicle-stimulating hormone and sex steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)","volume":"131","author":"Gonzalez-Barcena","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.xfre.2023.02.007_bib23","first-page":"2343","article-title":"Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics","volume":"83","author":"Hayes","year":"1998","journal-title":"J Clin Endocrinol Metab"}],"container-title":["F&S Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334123000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666334123000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:06:25Z","timestamp":1762981585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666334123000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2666334123000156"],"URL":"https:\/\/doi.org\/10.1016\/j.xfre.2023.02.007","relation":{},"ISSN":["2666-3341"],"issn-type":[{"value":"2666-3341","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome","name":"articletitle","label":"Article Title"},{"value":"F&S Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xfre.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.","name":"copyright","label":"Copyright"}]}}